Clariant AG (0QJS)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 10.27 |
|---|---|
| 52-week range | 6.56 – 11.03 |
| Return, 1 month / 3 months | −4.6% / +37.4% |
| Return, 1 year / 3 years | +42.4% / −17.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 46 |
| Volatility (1 year) | 34.6% |
| Worst drawdown (1 year) | -20.2% |
| Average daily value traded | 3.15M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Clariant AG is a specialty chemicals company based in Switzerland. It makes additives, catalysts, pigments and masterbatches, along with other specialty chemical products. Its customers are manufacturers in industries such as plastics, coatings, automotive, textiles and consumer care, who use these materials to improve the performance and appearance of their own products. The company serves industrial markets in many countries around the world.
Clariant AG trades under the code 0QJS on the London Stock Exchange in UK, with its price quoted in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Clariant AG (0QJS) trades on the London Stock Exchange in UK. It last closed at GBP 10.27 on 27 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 169 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.4% and over the last three months it rose 37.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 87 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 20.3% | ||
| From 52-week high | -6.0% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 37.4% | ||
| 6-month return | 29.0% | ||
| 12-month return, skipping the last month | 49.2% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.2% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.15M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.9% |
|---|---|
| 1 month | −4.6% |
| 3 months | +37.4% |
| 6 months | +29.0% |
| 1 year | +42.4% |
| 3 years | −17.0% |
| 5 years | −43.1% |
Signals
| 50-day / 200-day average | 10.51 / 8.53 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.23 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2026 | GBX 0.0042 |
| 2 Jun 2025 | GBX 0.0042 |
| 30 May 2024 | GBX 0.0042 |
| 2 Jun 2023 | GBX 0.0042 |
| 8 Sep 2022 | GBX 0.0040 |
| 30 Jun 2021 | GBX 0.0070 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.